Fisher Wallace Laboratories

Updates

🔵 Business Update

2 months ago

Dear Investors,

Last week we experienced stable revenue despite the dramatic downturn in the economy, and I attribute this to several factors: 1) while people are being directed to stay home, our device is one of the only treatment option for stress, mood and sleep that may be obtained via a telemedicine prescription (without leaving home) and without a trip to the pharmacy (as we ship the device directly to their home) 2) reducing or eliminating stress, anxiety, depression and insomnia positively impacts immune system health - a critical consideration for customers today 3) many states have waived their archaic telemedicine laws and now allow doctors to operate remotely across state lines 4) we are offering a significant "Crisis Relief Discount" on all orders 5) we've seen growing sales for our wellness brand, Circadia ®, which does not require a prescription.

By next week, we will inventory Circadia® with Amazon (where our device is currently out of stock) and direct more people to Amazon to buy it - obviously, most of America now depends on Amazon for all of their shopping needs, so this should become a growing distribution channel for Circadia® moving forward. We cannot sell the Fisher Wallace Stimulator on Amazon as Amazon is not permitted to sell prescription medical devices - this is a good thing, as it allows us to keep more margin on this brand by managing our own e-commerce and pass along savings to the customer instead of fees to Amazon.

As always, if you have friends, family members, colleagues or employees in need of stress and/or sleep management, please refer them to Circadia®, and give them an exclusive $400 discount in the process (we know these are very challenging economic times). Here’s the link that provides the $400 discount: https://circadia.info/products/circadia-399-free-ship. There’s a 100% free return / refund policy, and no prescription is required to purchase Circadia®.

I plan to update you on a week by week basis during this crisis - thanks for your consideration.

Best regards,

Kelly Roman

CEO, Fisher Wallace

BTW, from The New York Times: "A healthy immune system can fight off infection. A sleep-deprived immune system doesn’t work as well. In one surprising study, researchers found 164 men and women willing to be exposed to the cold virus. Not everyone got sick. But short sleepers — those who regularly slept less than six hours a night — were 4.2 times more likely to catch the cold compared with those who got more than seven hours of sleep, researchers found. Risk was even higher when a person slept less than five hours a night."

Business Update, $400 Product Discount, and Word-of-Mouth Request

2 months ago

Dear Investor,

I hope you and your family are healthy and secure. Getting quality sleep and reducing stress are two of the most important things you can do to improve your immune system - as recently highlighted in The New York Times.

Our technology improves sleep and reduces stress (specifically, it reduces cortisol, the stress hormone, as demonstrated in published research) - and we ship our device directly to the customer’s home, an essential convenience today. Healthcare needs to be delivered when social distancing is the new normal.

Business Update

Our factory is currently open, our supply chain is currently intact, and customers are buying devices. Last week, we launched a new 100% free returns policy. This means we now provide a free return shipping label and no longer charge any return / restocking fees. Customers can try our technology knowing that they may return it for a full refund, free of charge. We are beginning to see early signs that this policy is positively influencing short term buying decisions.

We Need Your Grassroots Support

Our wellness device, Circadia®, clones the technology of our medical device but may be obtained without a prescription, as it’s marketed for stress and sleep management (a wellness claim) as opposed to depression, anxiety and insomnia (a medical claim). In other words, Circadia® and the Fisher Wallace Stimulator® are identical hardware, producing the same output, but are labeled differently, which allows Cicadia® to be obtained without a prescription.

If you have friends, family members, colleagues or employees in need of stress and/or sleep management, please refer them to Circadia®, and give them a $400 discount in the process (we know these are very challenging economic times). Here’s the link that provides the $400 discount: https://circadia.info/products/circadia-399-free-ship

Again, there’s a 100% free return / refund policy, and no prescription is required to purchase Circadia®.

Discussing stress and sleep is a lot easier than discussing depression and anxiety, which is why Circadia® is an important product in our portfolio. It makes “word of mouth” much easier to facilitate, while providing the identical hardware as our flagship medical product.

Of course, feel free to use the discount link yourself - or buy Circadia® as a gift for someone. One great benefit of the device is that multiple people can use a single device so long as the electrode sponges are replaced regularly - great for couples, for instance, when both partners need stress and sleep management.

Please let me know if you have any comments, questions or concerns.

And remember, getting enough sleep is one of the best things you can do to stay healthy. Don’t fear the 30-90 minute nap.

Best regards,

Kelly Roman

CEO, Fisher Wallace

One day left to join our waitlist!

3 months ago

Dear Investors,

If you have not already invested in Fisher Wallace and wish to, you have one day left to join the waitlist. Waitlist investors are turned into active investors if any of the current investors are not cleared through the confirmation process, which almost always occurs with some investors.

It's wonderful to be oversubscribed, and I hope some of you will be able to join us as investors through the waitlist process!

Best,

Kelly Roman

CEO, Fisher Wallace

🔵 Thank you! We just passed $1Million in funds raised.

3 months ago

To all of our investors, thank you - because of your belief in our product and our future, we just passed $1 Million in funds raised, with 3 days left in the campaign.

I look forward to the next phase of the journey.

Much appreciated,

Kelly Roman
CEO
Fisher Wallace Laboratories

Our campaign closes in 4 days - and we are very close to $1M raised!

3 months ago

Dear Investors,

We have four days left in our campaign, and we are not extending it - thanks for your consideration. As of today, we are close to hitting the $1M mark.

As you know, our technology is drop-shipped to patients directly for us at home - a convenience of even greater value in these times for customers who wish to limit their travel to obtain treatment.

Please let me know if you have any questions!

Best,

Kelly Roman

CEO, Fisher Wallace

Last Chance to Invest

3 months ago

Dear Investors,

Fisher Wallace is closing its equity crowdfunding campaign in a few days from now. Even if you don't invest, I invite you to visit our campaign page to learn more about our mission. This is the last email we will send to request your consideration to invest - we appreciate your attention.

Compared to drug therapy, psychotherapy, TMS and ECT, Fisher Wallace offers a unique treatment option: extremely safe (almost no side effects), very effective, affordable (not yet "cheap" but well worth it if it succeeds), and convenient to use in the privacy of your own home. We know you understand the value, and hope you will support our journey as we enter the next phase of commercializing this product with better design, patient monitoring, data analytics, and most importantly, ubiquity. Once we are able to reduce the cost of the device to under $400 for most patients (achievable with manufacturing and marketing innovations) we believe this technology will supplant the standards of care that are currently covered by insurance. Thanks in advance for helping us get there!

We've valued the company at a modest $15M for this raise to incentivize participation - the market for mental health treatment in the US is enormous, more than cancer, heart disease or diabetes. Thanks again for your consideration!

Much appreciated,

Kelly Roman
CEO
Fisher Wallace Laboratories
Connect with me on LinkedIn

Treating Veterans and First Responders

3 months ago

Fisher Wallace has a long history of treating the veteran and first responder communities. Retired US Army General Stephen N. Xenakis, MD, was one of the first members of our volunteer medical advisory board and has had great success treating veterans in his private practice with our technology. Dr. Xenakis is currently assisting Fisher Wallace in setting up a first-of-its-kind clinical trial at a large military hospital.

Last month, Fisher Wallace completed a clinical trial that treated 30 active duty police officers, with results currently being prepared for publication.

As we endeavor to grow the business over the next year and beyond, we intend to leverage the data from the police study to drive adoption by police departments nationwide - there are over a million uniformed police officers in the US, many of whom are in need of safe, effective sleep and stress management tools.

We invite you to listen to retired US Marine Logan Shield and Dr. Xenakis discuss using our device to treat mood and sleep symptoms as part of our StartEngine video, as well as Vietnam Veteran Mike Davis.

We have included the biographies of Dr. Xenakis and advisory board member Dr. Meir Kryger, Yale School of Medicine, below.

Thanks for your consideration and please let us know if you have any questions.

Stephen N. Xenakis, M.D.

Dr. Xenakis served 28 years in the United States Army as a medical corps officer. He held a wide variety of assignments as a clinical psychiatrist, staff officer, and senior commander including Commanding General of the Southeast Army Regional Medical Command. Dr. Xenakis has written widely on medical ethics, military medicine, and the treatment of detainees. He has published editorials in the Washington Post and a number of other national magazines and journals, including book chapters and legal reviews. Dr. Xenakis has an active clinical and consulting practice, and is currently working on the clinical applications of quantitative electroencephalography (QEEG) to brain injury and other neurobehavioral conditions.

Meir Kryger, M.D., FRCPC

Meir Kryger, MD, FRCPC, joined the Yale School of Medicine and the VA Connecticut Health System, November 2011. Previously he was Professor of Medicine, University of Manitoba where he established the first clinical laboratory studying patients with sleep breathing problems in Canada. Dr. Kryger has published more than 200 research articles and book chapters. He is the chief editor of the most widely used textbook in sleep medicine, The Principles and Practice of Sleep Medicine, currently in its 5th edition and is the author of A Woman's Guide to Sleep Disorders, the Atlas of Clinical Sleep Medicine, and Kryger’s Sleep Medicine Review. Dr. Kryger was the first to diagnose and report obstructive sleep apnea in North America. His research was the first to show the feasibility of using noninvasive techniques to ventilate post-polio patients in their homes. His laboratory elucidated the interaction between heart failure and sleep respiration publishing the first systematic study of oxygen in this condition. He has been president of both the Canadian Sleep Society and the American Academy of Sleep Medicine. He is on the Board of Directors of the National Sleep Foundation in Washington, D.C., and served as Board. He received the William C. Dement Award for Academic Achievement in sleep medicine. In 2011 he received a Distinguished Scientist Award from the Canadian Sleep Society at the meeting of the World Association of Sleep Medicine.

Notice of Funds Disbursement

3 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, Fisher Wallace Laboratories has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in Fisher Wallace Laboratories be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

What depression, anxiety and insomnia treatment can look like

3 months ago

In 2015, Fisher Wallace collaborated with streetwear brand Mishka NYC to create a limited edition medical device that appealed to healthcare consumers aged 21 - 34. The devices sold out quickly. Look forward to similar collaborations in 2020 as we diversify our approach to wellness and medical neurostimulation products.

Reducing stigma one device at a time.

Watch the video below to learn more about the collaboration.

▪ How do we reduce or reverse the stigma?

3 months ago

The youth want better treatment options - safer, more effective, more affordable.

And ones that are more fun to experience.

Fisher Wallace is thinking about how to make effective, low-risk, affordable mental health treatment appealing to patients aged 21+ who don't want drug therapy to be their only option.

Reducing the stigma of mental health treatment is a challenge we are ready to tackle.

Thanks for your consideration!

Best,

Kelly Roman

CEO, Fisher Wallace

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{comment.user.first_name}} {{comment.user.last_name}} se owner {{comment.user.active_investments_count}} {{ comment.user.active_investments_count > 1 ? 'investments' : 'investment' }} Invested - Fisher Wallace Laboratories {{comment.created_at_in_words}}
You reported this comment as inappropriate.

{{reply.user.first_name}} {{reply.user.last_name}} - Fisher Wallace Laboratories {{reply.created_at_in_words}}
You reported this comment as inappropriate.

Company	:	Fisher Wallace Laboratories, Inc.
Corporate Address	:	515 Madison Avenue, New York, NY 10022
Offering Minimum	:	$10,000.00
Offering Maximum	:	$1,070,000.00
Minimum Investment Amount (per investor)	:	$250.00

Offering Type	:	Equity
Security Name	:	Class B Non-Voting Stock
Minimum Number of Shares Offered	:	4,000
Maximum Number of Shares Offered	:	428,000
Price per Share	:	$2.50
Pre-Money Valuation	:	$15,000,000.00